Samantha Zullow MD

Inflammatory Bowel Disease

Gastroenterologist and IBD specialist

330 Brookline Ave# DANA501Boston, MA 02215
Phone+1 617-754-4232

Dr. Zullow is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Zullow's full profile Already have an account?

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Inflammatory Bowel Disease, 2021 - 2022
NYU Grossman School of MedicineFellowship, Gastroenterology, 2018 - 2021
Boston University Medical CenterChief Residency, Internal Medicine, 2017 - 2018
Boston University Medical CenterResidency, Internal Medicine, 2014 - 2018
University of Maryland School of MedicineClass of 2014

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2020 - 2027
NY State Medical License 2018 - 2023
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Gastroenterology

Publications & Presentations

PubMed

Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel disease.
Tina Deyhim, Alessandra Saraga, Ajay Gade, Grace Geeganage, Mostafa A Soliman
European Journal of Gastroenterology & Hepatology. 2026-09-01
Higher body mass index is associated with lower drug concentrations in patients with inflammatory bowel disease treated with ustekinumab but not vedolizumab.
Joyce Lee, Rachel Porth, Alessandra Saraga, Ajay Gade, Tina Deyhim
Inflammatory Bowel Diseases. 2026-07-02
Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated with Less Treatment Failure in Patients with Inflammatory Bowel Disease Treated with Adalimumab.
Ajay Gade, Alessandra Saraga, Tina Deyhim, Grace Geeganage, Samantha Zullow
Digestive Diseases and Sciences. 2026-06-01

Abstracts/Posters

Histologic Inflammation Defined by the Robarts Histopathologic Index may Predict Future Clinical Relapse in Ulcerative Colitis Patients in Endoscopic Remission
George L, Feldman H, Hine AM, Zullow S, Stashek KM, Sun K, Suparna SA. Sarkar, Abutaleb A, Hudesman D, Axelrad JE, Cross RK, Digestive Disease Week 2020, Cancelled due to COVID Pandemic, 5/1/2020
The Real-World Effectiveness of Ustekinumab in Ulcerative Colitis
Hong S, Zullow S, Axelrad JE, Chang S, Hudesman D, Crohn's & Colitis Congress, Austin, Texas, 2/1/2020
Mild Endoscopic Activity Is Associated With an Increased Risk of Relapse in Patients With Ulcerative Colitis
Feldman, H, George L, Abutaleb A, Hine AM, Zullow S, Axelrad JE, Hudesman D, Cross RK, American College of Gastroenterology, San Antonio, Texas, 10/23/2019